Epidemiology of systemic sclerosis

Current Opinion in Rheumatology

Volumn 8, Issue 6, 1996, Pages 585-589

  Silman, Alan J ^a   Newman, Jason ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN;

AUTOIMMUNITY; BREAST ENDOPROSTHESIS; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; SILICONE PROSTHESIS; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; BREAST IMPLANTS; CONTINENTAL POPULATION GROUPS; HLA ANTIGENS; HUMANS; OCCUPATIONAL EXPOSURE; RISK FACTORS; SCLERODERMA, SYSTEMIC; SILICONE ELASTOMERS;

EID: 0030483143     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199611000-00015     Document Type: Review

References (38)

1. Silman AJ, Black CM, Welsh KI: Epidemiology, demographics, genetics. In Systemic Sclerosis. Edited by Clements PJ, Furst DE. Baltimore: Williams & Wilkins; 1996:23-49. A recent review of the occurrence of scleroderma and the contribution of genetic and environmental factors.
2. Geirsson AJ, Steinsson K, Guomundsson S, Sigurosson V: Systemic sclerosis in Iceland: a nationwide epidemiological study. Ann Rheum Dis 1994, 53:502-505.
3. Chandran G, Ahern MJ, Smith M, Roberts-Thomson PJ: A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust N Z J Med 1995, 25:688-694.
4. Maricq HR, Weinrich MC, Keil JE, et al.: Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989, 32:998-1006.
5. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC: Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992, 35:216-218.
6. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger T: Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994, 37:902-906.
7. Stephens CO, Briggs DC, Whyte J, Artlett C, Scerbakov AB, Olsen N, Gusseva NG, McHugh NJ, Maddison AB, Welsh KI, Black CM: Familial scleroderma: evidence for environmental versus genetic trigger. Br J Rheumatol 1995, 33:1131-1135.
8. Cook NJ, Silman AJ, Propert J, Cawley MID: Features of systemic sclerosis (scleroderma) in an identical twin pair. Br J Rheumatol 1993, 32:926-928.
9. Feghall AC, Wright TM: Epidemiologic and clinical study of twins with scleroderma. Arthritis Rheum 1995, 38(suppl):308.
10. Briggs D, Stephens C, Vaughan R, Welsh K, Black C: A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. Arthritis Rheum 1993, 36:943-954.
11. De Juan MD, Belzunegui J, Belmonte I, Barado J, Figueroa M, Cancio J, Vidal S, Cuadrado E: An immunogenetic study of familial scleroderma. Ann Rheum Dis 1994, 53:614-617.
12. Manolis N, Dunckley H, Chivers T, Brooks P, Englert H: Immunogenetic analysis of 5 families with multicase occurrence of scleroderma and/or related variants. J Rheumatol 1995, 22:85-92.
13. Takeuchi F, Nakano K, Yamada H, Hong GH, Nabeta H, Yoshida A, Matsuta K, Bannai M, Tokunaga K, Ito K: Association of HLA-DR with progressive systemic sclerosis in Japanese. J Rheumatol 1994, 21:857-863.
14. Satoh M, Akizuki M, Kuwana M, Mimori T, Yamagata H, Yoshida S, Homma M, Yamamoto T, Sasazuki T: Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. J Rheumatol 1994, 21:111-114.
15. Vargas-Alarcon G, Granados J, Ibanez de Kasep G, Alcocer-Varela J, Alarcón-Segovia D: Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. Clin Exp Rheumatol 1995, 13:11-16. The association between major histocompatibility complex class I, II, and III antigens and systemic sclerosis was measured in 41 Mexican mestizo patients with scleroderma, 113 of their first-degree relatives, and 85 ethnically matched controls. HLA-DR5 and HLA-DRw52 frequencies were higher in scleroderma patients compared with the matched controls (relative risk, 3.31, and 95% Cl, 1.3 to 8.3; versus relative risk, 2.4, and 95% Cl, 1.0 to 5.7). Ten of the 41 patients (24.3%) had DRB1*1104 subtypes compared with six of 85 healthy controls (7.0%) (relative risk, 4.25).
16. Reveille JD, Durban E, MacLeod-St Clair MJ, Goldstein R, Moreda R, Altman RD, Arnett FC: Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase 1: autoantibody response in scleroderma (systemic sclerosis). J Clin Invest 1992, 90:973-980.
17. Kuwana M, Okana Y, Kabruraki J, Inoko H: HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). Ann Rheum Dis 1995, 54:983-987.
18. McHugh NJ, Whyte J, Artlett C, Briggs DC, Stephens CO, Olsen NJ, Gusseva NG, Maddison PJ, Black CM, Welsh K: Anticentromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 1994, 96:267-274.
19. Morel PA, Chang HJ, Wilson JW, Conte C, Falkner D, Tweardy DJ, Medsger TA Jr: HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. Hum Immunol 1995, 42:35-42. Scleroderma patients (47 with ACA and 57 negative for both ACA and antitopoisomerase I antibodies) underwent HLA typing. Normal controls consisted of 181 healthy individuals. A significant association was observed in the ACA-positive patients with DQB1*0501 (relative risk, 2.6; P = 0.001), and a significant negative association was observed with DQB1*0201 (relative risk, 0.33; P = 0.01). These HLA associations persisted after stratification of the ACA-positive patients.
20. Morel PA, Chang HJ, Wilson JW, Conte C, Saidman SL, Bray JD, Tweardy DJ, Medsger TA Jr: Severe systemic sclerosis with anti-topoisomerase 1 antibodies is associated with an HLA-DRw11 allele. Hum Immunol 1994, 40:101-110.
21. Gendi NST, Welsh KI, Van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM: HLA type as a predictor of mixed connective tissue disease differentiation: ten-year clinical and immunogenetic follow-up of 46 patients. Arthritis Rheum 1995, 38:259-266.
22. Von Rihs HP, Conrad K, Mehlhorn J, May-Taube K, Welticke B, Frank KH, Baur X: Molecular analysis of HLA-DPB1 alleles in idiopathic systemic sclerosis patients and uranium miners with systemic sclerosis. Int Arch Allergy Immunol 1996, 106:216-222. Allele typing for HLA-DBP1 was done in 54 patients with idiopathic systemic sclerosis, 26 uranium miners with systemic sclerosis (either anti-Scl-70 positive or negative), and 70 unrelated healthy controls. Frequencies of DPB1*1301, *0601, and *0701 alleles were enhanced in anti-Scl-8-positive systemic sclerosis cases compared with healthy controls. A strong association between anti-Scl-70 positivity in systemic sclerosis patients and the glutamic acid residue of DPB1 was thus observed in comparison both with anti-Scl-70-negative systemic sclerosis patients (P = 0.0009) and with controls (P = 0.0007).
23. Von Rihs HP, Conrad K, Mehlhorn J, May-Taube K, Welticke B, Frank KH, Baur X: Unterschiedliche HLA-D-Phanotypfrequenzen bei anti-Scl-70 und ACA-positiven Patienten mit progreeiver systemisher Sklerodermie met ohne Tatigkeit im Uranerzbergbau. Arbeitsmed Sozialmed Umweltmed Sonderheft 1994, 22:23-26.
24. Bovenzi BM, Barbone F, Betta A, Tommasini M, Versini W: Scleroderma and occupational exposure. Scand J Work Environ Health 1995, 21:269-292. A case referent study conducted in Italy. Cases of scleroderma (n = 21) were taken from computerized admission files from all the local hospitals (1976 to 1991). Each case was matched with two age- and gender-matched controls, discharged at the same time. Subject occupational histories were ascertained through structured questionnaires. A significant association was found (odds ratio, 9.28; 95% Cl, 1.08 to 243.8) in three men and one woman with scleroderma who had been exposed to organic solvents.
25. Laing T, Gillespie B, Burns C, Garabrant D, Heeringa S, Alcser K, Schottenfeld D, Mayes M: Risk factors for scleroderma among Michigan women [abstract]. Arthritis Rheum 1995, 38(suppl):341.
26. Waller PA, Clauw D, Cupps T, Metcalf JS, Silver RM, Leroy EC: Fasciitis (not scleroderma) following prolonged exposure to an organic solvent (trichloroethylene). J Rheumatol 1994, 21:1567-1570.
27. Archer C, Gordon DA: Silica and progressive systemic sclerosis (scleroderma): evidence for workers compensation policy. Am J Ind Med 1996, 29:533-538.
28. Field T, Bridges AJ: Clinical and laboratory features of patients with scleroderma and silicone implants. Curr Top Microbiol Immunol 1996, 210:283-290.
29. Gabriel SE, O'Fallon M, Kurland LT, Beard CM, Woods JE, Melton LJ: Risk of connective tissue diseases and other disorders after breast implantation. N Engl J Med 1994, 330:1697-1702.
30. Sanchez-Guerro J, Colditz GA, Karlson EW, Hunter DJ, Speizer FE, Liang MH: Silicone breast implants and their risk of connective-tissue diseases and symptoms. N Engl J Med 1995, 332:1666-1670. Data were analyzed from a 14-year follow-up (1976 to 1990) of the Nurse's Health Study cohort. Data were collected before the media began reporting on possible health risks from implants. Information on 87,501 women was collected from postal questionnaires and blinded medical record reviews; 1183 of those surveyed had received an implant. There were 516 subjects with definite connective tissue disease, of whom 14 had scleroderma. None of these 14 women had had an implant.
31. Hochberg MC, Perlmutter DL: The association of augmentation mammoplasty with connective tissue disease, including systemic sclerosis (scleroderma): a meta-analysis. Curr Top Microbiol Immunol 1995, 210:411-417.
32. Hochberg MC, Perlmutter B, White B, Steen V, Medsger TA, Weisman M, Wigley FM: The association of augmentation mammoplasty with systemic sclerosis: results from a multicentre case-control study. Arthritis Rheum 1994, 37(suppl):369.
33. Englert HJ, Brooks P: Scleroderma and augmentation mammoplasty: a causal relationship? Aust N Z J Med 1994, 24:74-80.
34. Goldman JA, Greenblatt J, Joines R, White L, Aylward B, Lamm SH: Breast implants, rheumatoid arthritis and connective tissue disease in a clinical practice. J Clin Epidemiol 1995, 48:571-582. Analysis was performed on the records of 4229 female patients from a US rheumatologic practice (1986 to 1992). Of 721 patients (mean age, 43.8 years) with a connective tissue disease, 64 had scleroderma. One hundred fifty women had had breast implantation (mean age, 47.2 years). The study found no evidence that women with breast implants are at an increased risk for scleroderma or other connective tissue diseases. No scleroderma cases had been diagnosed among women with implants.
35. Burns CG: The epidemiology of systemic sclerosis: a population based case-control study [doctoral dissertation]. Ann Arbor, MI: University of Michigan; 1994.
36. Hennekens CH, Cook NR, Hebert PR, Karlson EW, LaMotte F, Manson JE, Buring JE: Self-reported breast implants and connective tissue disease in female health professionals. JAMA 1996, 275:616-621. A retrospective cohort study (1962 to 1991) of 395,543 female US health professionals (90.7% white and non-Hispanic; mean age, 51.7 years) who completed postal questionnaires. The study reported that 10,830 women had had breast implants and that 11,805 had connective tissue disease. Ten women with implants and 314 without implants had scleroderma (relative risk, 1.84; 95% Cl, 0.98 to 3.46). Five women with systemic sclerosis had had implants for less than 4 years (relative risk, 2.68; 95% Cl, 1.11 to 6.51). No clear trends could be shown with increasing interval since implantation. The study concluded that these data exclude the possibility of a high risk of connective tissue disease in women who have had breast implants.
37. Giltay EJ, Bernelot Moens HJ, Riley AH, Tan RG: Silicone breast prostheses and rheumatic symptoms: a retrospective follow-up study. Ann Rheum Dis 1994, 53:194-196.
38. Wells KE, Cruse CW, Baker JL Jr, Daniels SM, Stern RA, Newman C, et al.: The health status of women following cosmetic surgery. Plast Reconstr Surg 1994, 93:907-912.